The endogenous compound adenosine may play a role in limiting myocardial ischemiareperfusion injury through its ability to cause vasodilation, modulate cardiac adrenergic responses, inhibit neutrophil function, or modulate energy supply and demand of the myocardium. The local anesthetic lidocaine has been shown to be protective against myocardial ischemia-reperfusion injury, although its mechanism of action remains unresolved. We hypothesized that administration of exogenous adenosine during reperfusion would limit the size of the infarct that results from a period of ischemia and reperfusion only when the animals are treated with lidocaine. Male, mongrel dogs (13.0-20.0 kg) were anesthetized (30 mg/kg i.v. sodium pentobarbital), and a left thoracotomy was performed. The left circumflex coronary artery (LCx) was isolated and instrumented with an electromagnetic flow probe, a 25-gauge nonobstructing intracoronary catheter, and a critical stenosis. The dogs were allocated randomly to one of four groups: 1) control, n = 13, (saline), 2) adenosine, n = 13, (0.15 mg/kg/ml/min i.c. for the first hour of reperfusion), 3) lidocaine, n=9, (2.0 mg/kg i.v. given immediately before coronary artery occlusion and just before reperfusion), or 4) adenosine plus lidocaine, n=11. The LCx was occluded for 90 minutes and reperfused for 6 hours. Regional myocardial blood flow (RMBF) was determined (n =6 per group) at 80 minutes of occlusion and at 45 minutes of reperfusion with radiolabeled microspheres. RMBF determinations revealed an increase in blood flow to the inner two thirds of the myocardium at 45 minutes of reperfusion only in the presence of the combined treatment. Adenosine treatment alone or lidocaine treatment alone did not affect RMBF. Quantification of infarct size (triphenyltetrazolium method) expressed as a percent of the area at risk revealed a significant limitation of infarct size only in the group treated with both adenosine and lidocaine: control, 47.8±6.6%; adenosine, 45.0±3.2%; lidocaine, 46.9±6.0%; and adenosine and lidocaine, 20.8 ±5.6%. Statistical analyses were performed with two-way analysis of variance to account for the two individual drug treatments. The findings show that intracoronary administration of exogenous adenosine, at the dose used, is only effective at limiting myocardial infarct size when administered to lidocaine-treated animals. (Circulation 1990;82:595-608) I schemia-induced myocardial injury is limited by early reperfusion of the ischemic tissue, thereby providing the rationale for the use of coronary angioplasty or the administration of thrombolytic agents. However, evidence suggests that myocardial From the
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One endogenous compound that may play a role in modulating ischemia-reperfusion injury is adenosine.
Adenosine, a catabolite of the body's energy-storing molecule ATP, has been postulated to be an important mediator of metabolic autoregulation of coronary blood flow. 5 Belardinelli et a16 discussed the actions of adenosine that may result in protection against myocardial cellular injury induced by ischemia and reperfusion. These effects include the ability of adenosine to 1) inhibit enzyme release, and the generation of toxic oxygen species by activated neutrophils,7-12 2) inhibit neutrophil aggregation, as well as neutrophil adherence to, and injury of, endothelial cells,13'14 3) reduce ATP depletion during ischemia and improve repletion of ATP on reperfusion,15,16 4) stimulate myocardial glycolysis,17 5 ) normalize the oxygen supply/demand ratio through its vasodilatory and antiadrenergic properties,18'9 and 6) inhibit platelet aggregation.20 Engler21 suggested that the no-reflow phenomenon is due to neutrophil-mediated obstruction of the microvasculature and subsequent endothelial cell injury and that interventions that shunt ATP catabolism to adenosine instead of inosine exert protective effects during reperfusion by attenuating neutrophilinduced damage.
The effects of adenosine listed above suggest that the administration of exogenous adenosine can have protective effects during an ischemia-reperfusion event. Specifically, adenosine administered during reperfusion may attenuate reperfusion injury and may, therefore, limit tissue injury as assessed by measuring myocardial infarct size. In a canine model of ischemia-reperfusion injury, Olafsson et a122 reported a 75% reduction in infarct size in response to adenosine administered to the ischemic tissue bed during the first hour of reperfusion. They speculated that adenosine prevented neutrophil activation and, therefore, endothelial cell damage, resulting in enhanced blood flow to the reperfused myocardium. To study this finding further, we performed similar experiments but were unable to confirm that adenosine alone had protective effects.
To prevent lethal arrhythmias, it is not uncommon for investigators (Olafsson et a122 included) to incorporate the administration of lidocaine into the experimental protocol. However, lidocaine and related local anesthetic agents have been shown to protect against myocardial injury associated with permanent regional ischemia,2324 and global25 or regional ischemia-reperfusion26-28 Lidocaine has been shown to reduce the release of lipid peroxidation products from ischemic-reperfused myocardium26 and to prevent ion movements associated with tissue damage. 25 Lidocaine reduces neutrophil adherence in vitro29 and in vivo30,31 as well as reduces lysosomal enzyme release and superoxide anion production by these inflammatory cells. 32, 33 Because we could not demonstrate a protective effect of adenosine alone, we chose to determine whether the combined drug treatment was responsible for the reported myocardial salvage. Using a canine model of myocardial infarction, we assessed the effects of the administration of adenosine, lidocaine, or both in combination on infarct size after a 90-minute period of ischemia followed by 6 hours of reperfusion.
Methods

Guidelines for Use of Experimental Animals
The procedures used in this study were in accordance with the guidelines of The University of Michigan Committee on the Use and Care of Animals. Veterinary care was provided by The University of Michigan Unit for Laboratory Animal Medicine. The University of Michigan is accredited by the American Association of Accreditation of Laboratory Animal Care. Animal care and use conform to the standards in "The Guide for the Care and Use of Laboratory Animals," DHEW publication no. NIH 78-23.
Surgical Preparation of Dogs
Male mongrel dogs (13.0-20.0 kg) were anesthetized with sodium pentobarbital (30 mg/kg i.v.) and ventilated with room air with a Harvard respirator (South Natick, Mass.). A left thoracotomy was performed, and the heart was suspended in a pericardial cradle. One to two centimeters of the left circumflex coronary artery (LCx) were isolated proximal to the first major diagonal branch. The LCx was instrumented from proximal to distal with an electromagnetic flow probe (Carolina Medical Electronics, Inc., King, N.C.); a 25-gauge, nonobstructing, intracoronary catheter; a Silastic, mechanical snare occluder; and a stenosis. The stenosis was adjusted to dampen pulsatile blood flow without affecting the mean flow and to reduce the hyperemic response to a mechanical 10-second occlusion by 50-60%. A stenosis of this magnitude has been characterized with quantitative arteriography and represents approximately a 55% reduction in vessel diameter and 80% reduction in cross-sectional area. 34 A stenosis has been shown to reduce the incidence of lethal reperfusion arrhythmias and hemorrhagic infarction. 35, 36 An intravenous catheter was placed into the left external jugular vein for blood sampling and drug administration. A cannula was inserted into either the left external carotid artery or the right femoral artery for blood pressure measurements. Animals receiving microspheres for regional myocardial blood flow (RMBF) determinations were instrumented with carotid and femoral artery blood withdrawal lines and a left atrial appendage infusion cannula for the administration of microspheres.3738 Electrocardiographic electrodes for the limb leads were placed subcutaneously.
Experimental Protocol
Immediately after surgical instrumentation, a random lottery drawing was used to assign the dog to one of four groups: 1) vehicle control, 2) adenosine, 3) lidocaine, or 4) adenosine and lidocaine combination. In Admdnistration ofradioakbeled latexmncrospheres inner two thirds of the myocardium (inner two thirds RMBF) was greater than the preset limit of 0.2 ml/min/g, a ticket for that animal's type of treatment was reentered into the lottery until each group contained six animals. A protocol summary is depicted in Figure 1 . Dogs underwent a 90-minute period of LCx occlusion followed by a 6-hour period of reperfusion. Groups 3 and 4 were treated with a lidocaine dose (2 mg/kg in saline), administered by a rapid intravenous infusion, 1 minute before LCx occlusion, and an additional dose was administered 1 minute before reperfusion. Groups 2 and 4 received an infusion of adenosine (0.15 mg/kg/ml/min in saline) through the intracoronary catheter starting at the time of reperfusion and continuing for the first hour of reperfusion. Note that animals in group 4 received both lidocaine and adenosine treatments. Blood samples were drawn for the determination of plasma lidocaine concentrations before lidocaine administration, at 15 minutes of occlusion, and at 15 and 45 minutes of reperfusion. Radiolabeled microspheres for the determination of RMBF were admin- Lidocaine concentration was determined in the plasma from animals in lidocaine and combined treatment groups at 15 minutes after occlusion and at 15 and 45 minutes after reperfusion. Number of determinations is indicated above the respective bar. No differences between groups were noted at any time point. FIGURE 1. Scheme of protocol used to assess cardioprotective effects of adenosine, lidocaine, or adenosine and lidocaine in combination. Canine heart was subjected to 90 minutes of regional ischemia by occlusion of the left circumflex coronary artery and reperfused for 6 hours. Animals received adenosine (0.15 mg/kg/ml/min for the first 60 minutes ofreperfusion), lidocaine (2.0 mg/kg just before occlusion and again just before reperfusion), or saline (appropriate volume) treatments as indicated for the respective treatment group. Radiolabeled microspheres for the determination of regional myocardial blood flow were administered 80 minutes after occlusion and 45 minutes after reperfusion. Six hours after reperfusion, animals were killed, myocardial infarct size was determined histochemically, and samples of heart muscle were obtained for the analysis of regional myocardial blood flow. istered at 80 minutes of LCx occlusion and 45 minutes after reperfusion. Through the course of the experiment, LCx blood flow (pulsatile and mean), arterial blood pressure, and the electrocardiogram (leads II, III, and aVF) were recorded continuously on a polygraph (model 7, Grass Instruments Co., Quincy, Mass.).
Preparation ofAdenosine and Lidocaine
The adenosine (hemisulfate salt) was obtained from Sigma Chemical Co. (St. Louis, Mo.) and stored dessicated at -20°C. The infusion was prepared just before use in pyrogen-free saline. The lidocaine was a 1% lidocaine hydrochloride solution (10 mg/ml) for injection, obtained from Abbott Laboratories, North Chicago, Ill. The appropriate volume was diluted to 10 ml in pyrogen-free saline for administration.
Infarct Size Deternination
At the end of the reperfusion period, ventricular fibrillation was induced by application of a 60-Hz, 10-V, square-wave train of pulses applied to the base of the heart with a bipolar silver electrode. The heart was excised rapidly, rinsed of excess blood, blotted dry, and weighed. Histochemical determination of infarct size was performed with the dual perfusion technique described previously.39 Briefly, the LCx was cannulated at the site where it had been occluded and perfused with 1.5% 2,3,5-triphenyltetrazolium chloride (TTC) in 20 mM phosphate buffer (pH 7.4), whereas the aorta was perfused simultaneously in a retrograde manner with 0.25% Evans blue dye. Solutions were maintained at 370 C and perfused at a constant pressure of 100 mm Hg for 5 minutes. This method of quantifying infarct size with TTC has been validated by other investigators.
It has been shown to differentiate viable from nonviable myocardial tissue based on the histochemical reaction between YTC and myocardial dehydrogenase enzymes.40-44 The heart was then cut, parallel to the atrioventricular groove, into 1-cm-thick sec-.V. t , t0B..s\,. .t et(L . _ A tions and fixed in 4% formalin. Planimetric analysis was performed the following day using a previously described method.45
Regional Myocardial Blood Flow RMBF was measured to determine the severity of ischemia during the LCx occlusion and to, thereby, indicate the presence of collateral blood flow in the region of distribution of the LCx. RMBF was determined with radionuclide-labeled latex microspheres (15-,um diameter, New England Nuclear, Boston) by the reference withdrawal method46 as described previously.37,38 Before infusion, microsphere suspensions were sonicated and vortexed to ensure their even distribution in the suspending medium. An aliquot of 1-2 million microspheres (cerium-141, tin-113, scandium-46, ruthenium-103, or niobium-95; randomized) diluted in 10.0 ml 370 C saline was administered into the left atrium, followed by two 10-ml flushes with the 0.9% saline solution. Reference blood samples were withdrawn from the carotid and femoral arteries beginning 60 seconds before microsphere infusion and ending 90 seconds after completion of the saline flushes.
After planimetric analysis of the heart slices, tissue samples weighing approximately 1.0 g were obtained from each transverse ventricular section. Samples representing the subendocardium, midmyocardium, subepicardium, and papillary muscle were obtained from the central portion of both the ischemic inferior wall and the remaining nonischemic area. The kidneys were also removed from the animals at the end of the experiment, and two samples from each renal cortex were taken and counted for gamma ray emmissions to ensure an even whole-body distribution of radiolabeled microspheres. Radioactivity levels of the tissue and blood samples were determined with a gamma spectrometer (model 1185, Tracor Instruments, Austin Inc., Austin, Tex.). Overlap corrections and calculations of RMBF were made with an Apple II+ computer.
Lidocaine Plasma Concentrations
Venous blood samples (9 ml) from animals in the lidocaine and combined treatment groups were collected in 3.8% sodium citrate (1.0 ml/9.0 ml blood) for determination of lidocaine plasma concentrations.
Samples were immediately centrifuged at 1,400g for 10 minutes, and the plasma was collected and stored at -20°C until analysis. Lidocaine concentrations were determined with a polarized fluorescence assay with a TRX analyzer (Abbott Laboratories).
Exclusion Criteria
A number of predetermined exclusion criteria were set before the study was initiated. These criteria helped to ensure reproducible, severe ischemia in the LCx bed. Grounds for exclusion included the presence of heart worms or the development of intractable ventricular fibrillation requiring more than three attempts (20 J, direct current, applied directly to the heart) to obtain cardioversion. Animals were excluded if, during the period of occlusion, they failed to develop the characteristic electrocardiographic ST segment changes (leads II, III, and aVF) associated with ischemia. Animals receiving microspheres were excluded if their inner two thirds RMBF was greater than 0.2 ml/min/g. Although not a preset criterion, one animal was excluded because of abnormal whole-body distribution of microspheres based on the data from the kidney tissue samples.
The criterion to exclude animals with an inner two thirds RMBF greater than 0.2 ml/min/g was used to ensure that the myocardium was severely ischemic. Previously, the inner one third,47 or the inner one half,48 of the myocardium having an RMBF of less than 0.15 ml/min/g has been classified as severely ischemic. Given the transmural gradient in blood flow, we chose 0.2 ml/min/g as an RMBF cutoff value for the inner two thirds of the myocardium.
Statistical Analysis
Statistical analyses were performed with analysis of variance (ANOVA) and two-way ANOVA. Two-way ANOVA is designed to test for the effects of individual treatments within a multiple treatment regimen (i.e., the effect of adenosine or lidocaine) and for interactions between multiple treatments (i.e., the effect of combined adenosine and lidocaine). After obtaining a significant effect with ANOVA, we performed multiple comparison tests between groups with the Dunnett's t test for the appropriate number of comparisons. The calculated adenosine concentration data were compared with the unpaired Student's t test. Linear regression analysis was performed on the infarct data plotted against the inner two thirds RMBF data. Differences for all tests were considered significant when p was 0.05 or less. All data are expressed as mean+SEM.
Because the presence of preexisting collateral blood flow in some dogs affects the severity of ischemia in those dogs, the statistical analysis of many canine infarct size studies includes an analysis of covariance (ANCOVA) to account for preexisting collateral blood flow (a covariate). In this study, the use of ANCOVA was inappropriate for the following reason. ANCOVA is intended for experimental designs in which the covariate is measured before the treatment. In this study, the collateral blood flow measurement was performed at 80 minutes of occlusion, 80 minutes after two of the four groups received lidocaine treatment that may have altered blood flow to the ischemic region. However, the preset exclusion criteria used in this protocol helped to eliminate animals with high collateral blood flow and ensure severe ischemia in all animals.
Results
Several experiments were performed in each treatment group before initiating the portion of the study with radiolabeled microspheres. Based on the preset exclusion criteria, dogs were excluded from both portions of the study. These exclusions are outlined in Table 1 . Thirty-five animals entered the portion of the study without microspheres. Thirteen of these were excluded, leaving seven in the control, seven in the adenosine, three in the lidocaine, and five in the adenosine-plus-lidocaine groups. Thirty-nine animals entered the portion of the study with microspheres, and 15 were excluded, leaving six animals in each of the four groups. Thus, there were a total of 13 animals in the control, 13 in the adenosine, nine in the lidocaine, and 11 in the adenosine-plus-lidocaine groups. The following results are the combined data from the animals that did and did not receive microspheres unless the two sets are presented separately.
Hemodynamics
The hemodynamic parameters of the four groups were compared by ANOVA followed by Dunnett's t tests. Analysis of the heart rate measurements indicated that the lidocaine group had a higher baseline heart rate than the control group ( Table 2 ). Neither of the other two treatment groups differed from the control group at baseline, and none of the three treatment groups differed from the control group at any other time point during the study protocol. Mean arterial pressure and rate-pressure product measurements did not differ among the four groups at baseline or at any other time point during the protocol. Of significant importance, the intracoronary administration of adenosine was not associated with a decrease in any of these parameters as may be expected from various actions of this compound. The only hemodynamic parameter that was altered among the groups by the administration of a treatment was the LCx blood flow as measured with the electromagnetic flow probe. To normalize the LCx blood flow values, they were calculated and expressed as milliliters per minute per gram of area at risk. Baseline LCx blood flow measurements were similar in each of the four groups. However, analysis of measurements made during the first hour of reperfusion indicated that the combined treatment resulted in a significantly higher coronary blood flow compared with each other group. An infusion of adenosine alone at the dose used moderately increased blood flow, but the increase was not significant. On termination of the adenosine infusion, the elevated blood flows returned to baseline values during approximately a 5-minute period, and no differences in blood flow were found among the groups at any of the subsequent time points of the protocol.
Plasma Lidocaine Concentrations
Plasma lidocaine concentrations were determined in animals from each of the two groups that received the drug (Figure 2 ). Statistical analysis showed no difference between the two groups at any time point. Therefore, the drug concentrations from both groups were pooled. At 15 minutes of occlusion, and at 15 and 45 minutes of reperfusion, the plasma lidocaine concentrations were 5.6±1.0, 6.6±2.1, and 1.7±0.4 ,g/ml, respectively. Plasma Adenosine Concentrations Plasma adenosine concentrations were crudely determined (Table 3 ) by calculation with the LCx blood flow, as determined by the electromagnetic Values are mean±SEM. n=13 for control, 13 for adenosine, 9 for lidocaine, and 11 for adenosine+lidocaine groups. AR, area at risk. *For normalization purposes, the coronary blood flow is expressed as ml/min/g of area at risk. tpc0.05 by Dunnett's t test compared with any other group at the same time point. flow probe, the rate of adenosine infusion (0.15 mg/ kg/min), and assuming a hematocrit level of 40% with no uptake of adenosine into the erythrocytes. The concentration was calculated with both the baseline coronary blood flow and the coronary blood flow at a time when adenosine-induced vasodilation was present (30 minutes of reperfusion). When calculated with the baseline blood flow, there was no difference between the groups: adenosine, 600±70 ,uM, n=13; adenosine plus lidocaine, 480+40 ,uM, n=11 (p=0.130). When calculated with the blood flow at 30 minutes of reperfusion, the adenosine plus lidocaine group actually had a significantly lower concentration because of the higher coronary blood flow than in the adenosine group: adenosine, 360±30 uM; adenosine plus lidocaine, 200±40 ,uM (p=0.0012). However, these calculated concentrations may not reflect the actual in vivo concentrations because of the nonequilibrium condition of an infusion into flowing blood, adenosine uptake into erythrocytes and endothelial cells, and possible adenosine degradation.
Regional Myocardial Blood Flow
The RMBF values for each of 26 animals that received microspheres are presented in Table 4 , with the corresponding area at risk and infarct size data. Based on our preset criteria of an inner two thirds RMBF of 0.2 ml/min/g or less, two of the animals were excluded. The RMBF data described here were obtained from the 24 remaining animals (six per group). The inner two thirds RMBF measurements were obtained by averaging the subendocardial (inner one third) and midmyocardial (middle one third) RMBF values. Of note again, the tissue samples taken represent the central ischemic zone and central normal zone.
Inner two thirds regional myocardial blood flow. In the occluded LCx bed, no differences (ANOVA, p=0.184) in the RMBF values were noted among the treatment groups at 80 minutes of ischemia ( Figure   3 ). The RMBF values were 0.08+0.03, 0.04±0.01, 0.05±0.02, and 0.11±0.03 ml/min/g for the control, adenosine, lidocaine, and adenosine-plus-lidocaine groups, respectively. All groups were severely ischemic. To test for the possibility thal lidocaine increased blood flow to the ischemic LCx bed, RMBF values for all animals that received lidocaine at occlusion (lidocaine and combined groups) were grouped and tested against the grouped values for animals that did not receive lidocaine at occlusion (control and adenosine groups). No difference was found (p=0.120), although those that received lidocaine tended to have higher blood flows.
At 45 minutes of LCx reperfusion, Dunnett's t tests, after a significant ANOVA (p=0.034), indicated that the adenosine alone and lidocaine alone treatments did not alter blood flow but that the combined treatment resulted in an increase in blood *Calculated plasma adenosine concentration based on the adenosine infusion rate and the coronary blood flow at baseline or at 30 minutes after reperfusion and assuming a hematocrit level of 40%. tData excluded from mean±SEM; regional myocardial blood flow of this animal>0.2 ml/min/g. *Significantly different (p=0.0012) than 30 min reperfusion value for the adenosine group. flow to the inner two thirds of the myocardium compared with the control group. The RMBF values were 0.66+0.12, 0.73-+0.12, 0.58+0.06, and 1.33± 0.32 ml/min/g for the control, adenosine, lidocaine, and adenosine-plus-lidocaine groups, respectively. The twofold increase in blood flow to the inner two thirds of the myocardium in the adenosineplus-lidocaine group has the potential to limit infarct size, because this is the region of the myocardium in which the infarct forms.
In the normal zone myocardium of the left ventricle (that not supplied by the LCx), no differences in the inner two thirds RMBF determinations were noted among the treatment groups at 80 minutes of LCx occlusion (ANOVA, p=0.608) or at 45 minutes of LCx reperfusion (ANOVA, p=0.800). This indi-cates that the administration of adenosine into the LCx bed did not recirculate and affect RMBF in the other coronary artery beds.
Outer one third regional myocardial blood flow. In the outer one third (subepicardium) of the occluded LCx bed, no differences (ANOVA, p=0.273) in the RMBF values were noted among the treatment groups at 80 minutes of ischemia, although the adenosine-plus-lidocaine group tended to have higher blood flows in this region (Figure 4 ). The RMBF values were 0.17 + 0.04, 0.17 ± 0.05, 0.18 ± 0.04, and 0.31+0.09 ml/min/g for the control, adenosine, lidocaine, and adenosine-plus-lidocaine groups, respectively. Despite the tendency toward higher flows in the epicardial region of the adenosine-pluslidocaine group, we do not believe that this contrib- *Animals with inner 2/3 RMBF>0.2 ml/min/g. uted to the limited infarct size observed in this group because infarcts usually do not extend into the subepicardial region as a result of 90 minutes of ischemia followed by reperfusion.
At 45 minutes of reperfusion of the LCx bed, Dunnett's t tests, after ANOVA (p=0.0012), indicate that the outer one third RMBF in the adenosine-plus-lidocaine group is higher than in the control and lidocaine groups (values were 0.58+0.06, 1.39+0.36, 0.61+0.07, and 2.14±0.38 ml/min/g for the control, adenosine, lidocaine, and adenosineplus-lidocaine groups, respectively). There is a striking difference in the reperfusion RMBF profile between the outer one third and the inner two thirds of the myocardium. Although administration of adenosine alone did not increase blood flow to the inner two thirds of the myocardium (Figure 3) , it did increase blood flow to the outer one third of the myocardium (Figure 4 ).
In the normal zone myocardium of the left ventricle (that not supplied by the LCx), no differences in the outer one third RMBF determinations were noted among the treatment groups at 80 minutes of LCx occlusion (ANOVA, p=0.348) or at 45 minutes of LCx reperfusion (ANOVA, p=0.895).
Myocardial Infarct Size
The infarct zone (IZ) is expressed as a percentage of the area of the left ventricle (LV) at risk of becoming infarcted (AR). The myocardial infarct size data are presented for the animals that did (Table 4 ) and did not receive microspheres ( Table 5 ). The data from the largest set of animals is presented in Figure 5 . This set includes the 24 dogs that received microspheres and had an inner two thirds RMBF of 0.2 ml/min/g or less as well as the dogs in each treatment group that did not receive microspheres (but were ischemic based on characteristic electrocardiographic ST segment changes). After ANOVA (p=0.003), Dunnett's t tests of all possible comparisons revealed that of the three treatments only the combined treatment reduced the IZ/AR ratio with respect to the control group and also that the combined treatment reduced the ratio with respect to the adenosine group and the lidocaine group. In addition, two-way ANOVA indicated (p=0.043) an effect of the combined treatment over and above that expected from the effects due to the individual adenosine and lidocaine treatments. The actual values for the percent IZ/AR were 47.8+6.6%, 45 .0±3.2%, 46.9+6.0%, and 20.8±5.6% for the control (n=13), adenosine (n=13), lidocaine (n=9), and adenosine-plus-lidocaine (n= 11) groups, respectively. The percent AR/LV ranged from 37.1 ± 1. 41 .8±2.2% and did not vary among treatment groups (ANOVA, p=0.058). The infarcted zones of control hearts were generally confluent and extended well into the midmyocardium and often into the subepicardium. However, hearts from the combined treatment group exhibited infarcts that were generally patchy and confined to the subendocardium, although they occasionally extended into the midmyocardium.
A subset of the above infarct size data is presented in Figure 6 . This subset only includes the data from the 24 animals in which RMBF was measured and was 0.2 ml/min/g or less. The values for the percent IZ/AR were 36.2±7.2%, 45.2+4.5%, 38.2±5.5%, and 18.4+8.2% for the control, adenosine, lidocaine, and adenosine-plus-lidocaine groups (n = 6 per group), respectively. Similar to the above data analysis, two-way ANOVA indicated that neither adenosine nor lidocaine alone altered infarct size but that the combined treatment significantly reduced infarct size (p=0.039). The ratio of percent AR/LV ranged from 37.1±1.2% to 42.0±2.7% and did not vary among treatment groups (ANOVA, p=0.358).
A second subset of the pooled infarct data includes just the animals that did not receive microspheres. In this subset, the values for the percent IZ/AR were 57.9+9.5%, 44 .7+4.9%, 64.2+7.6%, and 23.6+8.1% 5 . Bar graph ofmyocardial infarct size data. Inclusive data from animals that received microspheres (6 per group) andfrom animals that did not receive microspheres but that were ischemic based on characteristic electrocardiographic ST segment changes. Infarct size (IZ) is expressed as a percentage of the area at risk (AR), and the AR is expressed as a percentage of the left ventricle (LV). *p'0.Q05 by Dunnett's t test compared with each group and also pc0.05 for two-way ANOVA (the combined drug effect being different than that expected from the effects of the individual drug treatments). Percent AR/LV did not vary among groups.
for the control (n=7), adenosine (n=7), lidocaine (n=3), and adenosine-plus-lidocaine (n=5) groups, respectively. After ANOVA (p=0.021), Dunnett's t tests indicated that only the adenosine-plus-lidocaine group had significantly smaller infarcts than the control group. The percent AR/LV for the groups ranged from 37.2+1.5% to 44.2±2.3% and did not vary among the groups (ANOVA, p =0.257).
The relation between myocardial infarct size and the inner two thirds RMBF at 80 minutes of occlusion is shown in Figure 7 according to the data obtained from the dogs that received microspheres and had an inner two thirds RMBF of 0.2 ml/min/g or less. Linear regression analysis of the data of the . Bar graph ofmyocardial infarct size data. Inclusive data are from only animals that received microspheres (6 per group). Infarct size (IZ) is expressed as a percentage of the area at risk (AR), and the AR is expressed as a percentage of the left ventricle (LV). *pc0.Q05 by two-way ANOVA. Percent AR/LV did not vary among groups.
individual treatment groups indicated that only the points of the control group lay significantly along a line (p =0.001, 0.085, 0.052, and 0.081 for the control, adenosine, lidocaine, and combined groups, respectively). For this reason and for clarity, only the line for the control data is depicted on the graph. However, it is evident that except for the one errant data point, the size of the infarcts in the combined treatment group lie along a line that would have a much different slope than the other three groups. Note that the x axis represents the inner two thirds RMBF, and all flows are less than 0.2 ml/min/g tissue.
Discussion
This study demonstrates that the administration of adenosine and lidocaine in combination results in the limitation of the size of experimental myocardial infarction at about 50% of the size of control infarcts. Administration of adenosine or lidocaine alone did not limit infarct size. These data must be interpreted with respect to the previous data of Olafsson et al,22
because their study served as a model for the present investigation. In their study, a 75% reduction in infarct size was attributed to the administration of adenosine (3.75 mg/min, in dogs weighing 23-30 kg) during the first hour of reperfusion. With a similar dose of adenosine (0.15 mg/kg/min) in our model of myocardial infarction, we were not able to confirm these findings. Careful scrutiny of their model revealed that the control and treatment groups were treated with morphine, diazepam, streptokinase, and lidocaine. The treatment group received adenosine in addition. Because there are many reports that lidocaine itself protects against myocardial ischemiareperfusion injury,23-28 and influences neutrophil function,29-33 we suspected that the lidocaine treatment used by Olafsson et a122 might have contributed to their findings. In an effort to resolve the conflict, we performed this study with the four treatment groups.
The administration of exogenous adenosine in hopes of protecting the ischemic-reperfused myocardium is not a novel concept. Such treatment has been examined in attempts to prevent various biochemical and functional changes of the myocardium associated with ischemia and reperfusion. These studies have met with success in partially restoring the biochemical alterations associated with an ischemia-reperfusion event, but negative and positive results have been obtained concerning functional recovery of the myocardium. 15, 49, 50 In addition to this lack of conclusive functional recovery after ischemia, only two previous studies have assessed the effect of adenosine on the size of experimental myocardial infarction. The first is the study of Olafsson et a122 in which adenosine (in lidocaine-treated animals) substantially reduced infarct size. The second is a study performed in rabbits, in which intravenous administration of adenosine was reported to "increase the extent of infarction and 'no reflow' zone" after occlusion and reperfusion.15 The dose of adenosine bed inner two thirds regional myocardial blood flow at 80 minutes of occlusion. Data points of the control group lay along the described line, whereas data points of other groups did not significantly fall along a line. Data points of the combined treatment group are generally shifted downward for any given value of regional myocardial blood flow (RMBF). Inner 2/3 RMBF at 80 min Occlusion (milminig) resulted in a decrease in heart rate. In addition, adenosine produced a decrease in blood pressure that might have caused the observed effect as a result of poor perfusion of the myocardium. At present, there are no data to show that adenosine alone reduces infarct size. Maybe the dose of adenosine that we used (0.15 mg/kg/min) was inadequate to afford myocardial protection, especially if one considers the short half-life (<15 seconds52) of adenosine in the blood. Neither the heart rate nor the mean arterial blood pressure was altered by the intracoronary administration of adenosine in this study, suggesting that adenosine was degraded or taken up into erythrocytes or endothelial cells by the time it reached the systemic circulation. Therefore, higher doses of adenosine may limit infarct size without adversely affecting the hemodynamic parameters. However, when the adenosine analogue 2chloroadenosine (a poor substrate for adenosine uptake systems and for adenosine deaminase) was used in the identical protocol at a dose of 6.0 gg/kg/min, a decrease in heart rate and a moderate decrease in blood pressure were observed, but again, no effect on infarct size was obtained (unpublished data). Physiological concentrations of adenosine have been shown to inhibit the respiratory burst by polymorphonuclear neutrophils, and the inhibitory effects of the nucleoside are characteristic of an adenosine A2-receptor-mediated response.53 An adenosine analogue specific for the A2-receptor subtype may provide greater cardioprotection.
In contrast to the lack of data on the effects of adenosine alone, several previous studies investigated the effects of lidocaine alone on myocardial infarct size.23,2627 Each of these studies report a limitation of infarct size as a result of treatment. However, differences in the dose, or administration regimen, are likely to account for the lack of effect of lidocaine alone in our study (2 mg/kg at occlusion and at reperfusion). In the previous studies, lidocaine administration consisted of a bolus dose (2.5 mg/ kg,23 50 mg,26 and 2 mg/kg27) before or early in the ischemic period, followed by a constant infusion (1.4 mg/kg/hr,23 0.07 mg/kg/min,26 and 0.2 mg/kg/min27) for the remainder of the ischemic period and throughout reperfusion (if performed). In the present study, we did not use a constant infusion of lidocaine, and although the plasma concentrations of lidocaine (determined shortly after administration) were similar to those reported in the previous studies, they represent peak values that are transient. With respect to this point and of particular interest here, MacGregor et a130 showed, using an ex vivo method of measuring granulocyte adherence, that a bolus dose of lidocaine (2.5 mg/kg) in rabbits inhibited adherence by 55% at 5 minutes with return to normal by 15 minutes. However, if the bolus dose of lidocaine was followed by an infusion of 0.3 mg/ kg/min, adherence remained inhibited by more than 50% for the remainder of the infusion. Similarly, in a canine model of ischemia-reperfusion, Bajaj et al54 demonstrated an increase in ex vivo neutrophil chemotaxis and lysozyme release at 1 hour after reperfusion despite a lidocaine bolus (5 mg/kg) at occlusion followed by a 30-minute infusion (0.12 mg/kg/min) and a bolus (3 mg/kg) at reperfusion followed by a 15-minute infusion (0.12 mg/kg/min).
The question remains as to why the combined treatment limited infarct size when the individual treatments did not. We believe that the inner two thirds RMBF data are relevant to this question. Because a myocardial infarct progresses from endocardium to epicardium,55 the inner two thirds of the myocardium is the region in which an infarct forms as a result of a 90-minute period of ischemia followed by reperfusion. Therefore, alterations of regional blood flow in this area would be expected to have the greatest impact on an evolving infarct. Analysis of the inner two thirds RMBF data obtained at 45 minutes of reperfusion indicated a significantly higher blood flow to this region of the myocardium only in animals that received both adenosine and lidocaine. The increased blood flow during reperfusion indicates that the combined treatment may protect the myocardium from irreversible injury by preventing progression of the no-reflow phenomenon. The RMBF data that we obtained are qualitatively similar to those that Olafsson et a122 reported.
In both studies, adenosine administration to lidocaine-treated animals significantly increased outer one third (subepicardial) RMBF. We demonstrate a significant increase in inner two thirds RMBF as well, whereas Olafsson et a122 reported a similar effect (albeit not significant) in the subendocardial RMBF. The observed increases in blood flows are in part due to the endothelium-independent vasodilatory properties of adenosine. Adenosine alone increased coronary blood flow as detected by the electromagnetic flow probe and by RMBF determinations in the outer one third of the myocardium. However, in the adenosine-plus-lidocaine treatment group, there was a large increase in RMBF over and above the effects of adenosine alone in both the inner two thirds and the outer one third of the myocardium. This indicates that some other mechanism must be responsible for a large part of the blood flow increase.
There are a number of studies reporting that adenosine can alter various neutrophil (PMN) functions. Several groups have shown that the production of reactive oxygen metabolites by stimulated PMNs is inhibited by adenosine, as is the release of various enzymes including lysozyme, myeloperoxidase, and ,/-glucuronidase.7-12'53 Also, adenosine has been shown to inhibit PMN aggregation713 as well as PMN adherence to and injury of endothelial cells.14 Similarly, the local anesthetic and membrane stabilizing agent lidocaine has been reported to also alter PMN function by reducing stimulated PMN superoxide anion production and release of lysosomal enzymes.32,33 Lidocaine inhibits neutrophil adherence to nylon fibers in vitro and to the endothelium in vivo as well as the delivery of PMNs to sites of inflammation.29-31 However, there are also studies showing that after ischemia-reperfusion, ex vivo neutrophil functions such as chemotaxis, lysozyme release, and superoxide production are not inhibited despite prior treatment of the animals with lidocaine.26 '54 Although the mechanism of the no-reflow phenomenon is not well understood, Engler21 has proposed that plugging of the myocardial microvasculature by activated PMNs, and the resulting injury to the endothelium, may play a role in the pathogenesis of the no-reflow phenomenon. Because of the effects of adenosine listed above, exogenous adenosine or treatments that would increase the local endogenous adenosine concentration should prevent the noreflow phenomenon and, therefore, reduce tissue injury. In a test of this hypothesis, Olafsson et a122 demonstrated decreased capillary plugging, decreased endothelial cell swelling and disruption, decreased PMN infiltration, decreased infarct size, reperfusion that they attributed to adenosine-induced inhibition of the no-reflow phenomenon. Our RMBF and infarct size data, using their adenosineplus-lidocaine treatment, are qualitatively similar to those of Olafsson et al. 22 However, this study showed that adenosine in the absence of the lidocaine treatment that they used did not provide any protective effect. We believe that the limit to tissue damage demonstrated by both groups was the result of a synergistic effect between adenosine and lidocaine that caused an adequate inhibition of PMN function, thereby preventing microvascular plugging and endothelial cell injury and increasing reperfusion blood flow. The mechanism(s) by which lidocaine synergizes with adenosine in vivo is not clear and will require further study. Quantitative differences between our data and those of Olafsson et a122 may reflect their use of multiple other drugs in addition to adenosine and lidocaine.
Two animals were excluded from the subset of animals that were administered radiolabeled microspheres, because they were not severely ischemic (they had an inner two thirds RMBF>0.2 ml/min/g) during the period of LCx occlusion. The excluded animals were one each from the lidocaine and adenosine-plus-lidocaine groups. Even though all of the remaining 24 animals were severely ischemic and there was no significant difference. in RMBF among the groups, the lidocaine and adenosine-plus-lidocaine groups overall tended to have slightly higher RMBF at 80 minutes of occlusion. This trend and the exclusions suggest that lidocaine treatment might have transiently increased the ischemic RMBF early during the period of occlusion (before the RMBF determination) while the lidocaine plasma concentrations were correspondingly high. Despite this possibility, enhanced RMBF at 45 minutes of reperfusion, and limitation of infarct size was only demonstrated in the adenosine-plus-lidocaine group. Thus, any possible effects of lidocaine on RMBF did not result in tissue salvage unless adenosine was also administered.
As well as causing vasodilation,5 adenosine has also been shown to have negative chronotropic and antiadrenergic effects.56'57 These properties may contribute to tissue salvage by decreasing the oxygen demand of the myocardial tissue. However, because no changes in the heart rate, mean arterial pressure, or rate-pressure product were noted with any of the treatments, these effects were minimal, and we do not believe that they greatly contributed to the findings.
It is well established that one result of myocardial ischemia is the net catabolism of the adenine nudleotide pool, resulting in an increase in the concentrations of the breakdown nucleosides. These are subsequently washed away during reperfusion and, therefore, are unavailable for nucleotide resynthesis. Efforts to prevent ATP depletion or accelerate the rate of ATP resynthesis have led investigators to administer exogenous intermediate substrates (such and an increase in functional recovery after ischemia-as adenosine) for the salvage pathways of nucleotide synthesis. Again, although adenosine administration might have helped to correct these biochemical changes, these effects of adenosine do not explain the blood flow increase or limitation of infarct size observed only in the combined treatment group.
With increased use of agents and procedures to achieve timely reperfusion of ischemic myocardial tissue, it has become increasingly important to understand the mechanisms underlying reperfusion injury so that this damage can be reduced or eliminated. This study expands on the previous hypothesis and findings that adenosine may be an important modulator of reperfusion injury caused by the no-reflow phenomenon. It also adds support to the growing body of literature implicating the neutrophil as an important contributor to the myocardial inflammatory response. Finally, it serves as a reminder of the difficulty in interpreting results from a study in which multiple drug treatments are used.
Critique of the Model
The results obtained in the present study support the observations reported by Olafsson et a122 in that the intracoronary administration of adenosine was associated with a reduction in myocardial infarct size in response to ischemia and reperfusion in the canine heart. The present study, however, suggests that the concomitant administration of lidocaine might have augmented the protective action that was formally attributed to adenosine. It should be pointed out that several methodological differences exist between this study and the previously reported observations.22 In the present study, the use of an open-chest qanine model of ischemia and reperfusion might have resulted in amplified neutrophil activation during the period of ischemia and reperfusion. This might have overwhelmed some of the potential beneficial effects of adenosine on neutrophil function. Another factor to be taken into consideration is that myocardial oxygen consumption is likely to be much higher in an open-chest compared with a closed-chest model. Suspension of the heart in a pericardial cradle as in the present study might have activated sympathetic reflexes and, thereby, influenced final infarct size. Finally, the present study used a reperfusion period of 6 hours rather than 24 hours. There is no assurance, therefore, that the combined treatment regimen prevented the extension of myocardial injury rather than simply delaying the development of cell death. Whether or not the methodological differences described herein could have contributed to the observations reported by us will require additional study to fully appreciate the potential of adenosine as a cardioprotective agent.
